Wild4ctix shared Leo's email (about five weeks ago
Post# of 72440
"Dr Menon's presentation is of a technical nature including how we improved the purity of Brilacidin and how we can make Brilacidin now in commercial quantities. The update provided today is far more informative to shareholders. Stating that we are taking a new class of antibiotic to a Phase 3 is a cause for excitement and I am amazed that some would care more about manufacturing techniques.
David, I always try to respond to shareholders. Regarding uplisting, I received emails regularly about this topic. Deep down I thought it's a bad idea to discuss this publicly as it may attract shorters.Then I compared the value of our assets to other publicly traded companies at the time, and I felt more comfortable. At that time I needed a $4 share price. Eventually the shorters knew that after my year end audit I would only need a $2 share price to get uplisted. They then engaged in the illegal act of market manipulation with the Seeking Alpha article. Our attorneys who know a lot about prosecuting assure me they will be dealt with."